Savara Inc (SVRA): Total Liabilities
$50.30M
As of 2025-12-31
$48.48M
As of 2026-06-30
+16.3%
3-year compound annual growth
+8.6%
5-year compound annual growth
+5.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.30M | +21.4% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $41.43M | +11.4% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $37.19M | +16.2% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $32.00M | -0.3% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $32.10M | -3.8% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $33.36M | -3.3% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $34.51M | -21.7% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $44.07M | +9.3% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $40.32M | +92.5% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $20.95M | -30.9% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $30.33M | +156.1% | 2017-03-06, Balance as of period end |
| 2014-12-31 | $11.84M | +59.1% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $7.44M | +43.7% | 2015-03-24, Balance as of period end |
| 2012-12-31 | $5.18M | +2.0% | 2014-03-26, Balance as of period end |
| 2011-12-31 | $5.08M | +181.9% | 2013-03-19, Balance as of period end |
| 2010-12-31 | $1.80M | n/a | 2012-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Savara Inc (SVRA) | 2025-12-31 | $50.30M | +21.4% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $201.25M | +38.2% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $697.32M | +10.4% |
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $20.15M | n/m |
| Verastem, Inc. (VSTM) | 2025-12-31 | $189.25M | +45.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $59.94M | +18.9% |
Compare SVRA, HRTX, MGNX, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗